Colon cancer is one of the most common cancers worldwide. Despite surgery, radiotherapy and chemotherapy, the chances of recovery are often limited. What is particularly stressful is that conventional therapies can work, but are difficult to tolerate for many patients. Even immunotherapies that have shown success in other types of cancer only help some of those affected. “There is an urgent need for new approaches that have a more targeted effect and fewer side effects,” says Martin Jung, head of the Molecular Diagnostics Competence Unit at the AIT Austrian Institute of Technology.
